ClinicalTrials.gg
RecruitingNCT07620626WEB-RWSUpdated Jun 11, 2026

Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment

An observational study in Intracranial Aneurysm, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Xuanwu Hospital, Beijing · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 100 studies in Intracranial Aneurysm with a site in China — 38 open to participants now, 42 under way, 1 of them phase 3. Intracranial Aneurysm · China.

Planned enrollment
20th of 51
1,000 · median 600
Started
2026
with 8 others
Observational
51 of 100
22 open now
Primary completion
2028-06
later than 33 of 41 live
Registered
95th of 100
by date
Lead sponsor
5 of 100
Xuanwu Hospital, Beijing

Among the 100 studies in Intracranial Aneurysm with a site in China, this one is the 20th largest by planned enrollment of the 51 observational ones that give a count, is one of 9 that started in 2026, is one of 51 observational ones, reaches primary completion later than 33 of the 41 other live ones, and was the 95th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

38 of the 100 studies in Intracranial Aneurysm with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies in Intracranial Aneurysm with a site in China, or all of them as a file.
02

Study summary

We designed the Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment (WEB-RWS), an ambidirectional, multicenter, post-market real-world study with a prospective active surveillance component. The study will include patients with IAs treated with commercially available WEB devices under the direction of treating physicians in routine clinical practice. Clinical, procedural, imaging, and safety data will be collected using a standardized electronic data capture system, with safety events adjudicated by an independent clinical events committee and imaging outcomes assessed by an independent core laboratory. The primary objective is to evaluate 12-month adequate aneurysm occlusion and major adverse events after WEB treatment. The study is expected to provide comprehensive post-market evidence on the real-world performance of the WEB device in China, including its safety, effectiveness, clinical appropriateness, and health economic value in routine neurointerventional practice.

Read the detailed description

Intracranial aneurysms are abnormal dilatations of blood vessels in the brain. If an aneurysm ruptures, it can cause subarachnoid hemorrhage, which may lead to serious disability or death. Endovascular treatment has become an important treatment option for intracranial aneurysms. The Woven EndoBridge (WEB) device is an intrasaccular flow disruption device designed to treat selected intracranial aneurysms from within the aneurysm sac.

This study is a post-market, ambispective, multicenter, real-world registry study. It will evaluate the safety and performance of commercially available MicroVention WEB devices when used by treating physicians according to routine clinical practice and the approved instructions for use. The study does not assign participants to a treatment group and does not require a randomized comparison. Treatment decisions are made by the treating physicians based on standard medical care.

The study plans to enroll up to 1,000 patients from multiple study centers in China. Approximately 200 patients will be included retrospectively, and approximately 800 patients will be included prospectively. Eligible participants are patients with intracranial aneurysms treated with a commercially available WEB device. For the prospective cohort, written informed consent will be obtained from the participant or legally authorized representative before study-related data collection, as applicable.

Clinical data will be collected using an electronic data capture system. Imaging data will be de-identified and submitted for independent core laboratory assessment. Follow-up assessments are planned after the procedure and at approximately 30 days, 6 months, and 12 months. Follow-up may include neurological assessment, imaging evaluation, information on aneurysm retreatment, adverse event assessment, serious adverse event assessment, and information on antiplatelet or anticoagulant medication use.

The primary effectiveness outcome is the proportion of aneurysms with adequate occlusion at 12 months, based on the Raymond-Roy Occlusion Classification. Adequate occlusion is defined as Raymond-Roy class I or II. The primary safety outcome is the rate of major adverse events, including unexpected death or major stroke within 30 days after the procedure, and neurological death or major stroke from 31 days to 1 year after the procedure.

Other outcomes include aneurysm occlusion based on the WEB Occlusion Scale, aneurysm recurrence, aneurysm retreatment, rebleeding, parent artery patency, clinical outcome measured by the modified Rankin Scale, device-related serious adverse events, procedure-related serious adverse events, neurological events, successful device implantation and health economic outcomes. The study will mainly use descriptive statistical methods to summarize outcomes and confidence intervals.

03

Conditions studied

  • Intracranial Aneurysm

Browse trials for

Keywords

  • Woven EndoBridge
  • WEB Device
  • Intrasaccular Flow Disruption
  • Endovascular Treatment
  • Intracranial Aneurysm
  • Aneurysm Embolization
  • Real-World Study
  • Post-Market Study
  • Raymond-Roy Occlusion Classification
  • WEB Occlusion Scale
  • Active surveillance
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population includes patients with intracranial aneurysms who are treated with the commercially available MicroVention Woven EndoBridge device as part of routine clinical care at participating study centers in China. The registry includes both retrospectively identified patients and prospectively enrolled patients. Clinical, procedural, imaging, and safety data will be collected according to the study protocol.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Retrospective Cohort:

  • Participants of any age and sex.
  • Patients treated for an intracranial aneurysm using a commercially available MicroVention Woven EndoBridge device.
  • Patients who completed at least one postoperative imaging follow-up.

Prospective Cohort:

  • Participants of any age and sex.
  • Patients treated for an intracranial aneurysm using a commercially available MicroVention Woven EndoBridge device.
  • The participant, or legally authorized representative if applicable, understands the study requirements and procedures and provides written before any study-specific data collection.

Exclusion criteria

Exclusion Criteria:

Retrospective Cohort:

  • Patients treated with a Woven EndoBridge device for whom intraoperative or postoperative follow-up imaging data are not available.
  • Patients considered by the investigator to be unsuitable for participation in this study.

Prospective Cohort:

  • Participants who are currently participating in, or plan to participate during the follow-up period, another clinical study that may affect the results of this study.
  • Patients who are currently unable or expected to be unable to complete follow-up.
  • Patients with a of less than 1 year due to other diseases or conditions.
  • Patients considered by the investigator to be unsuitable for participation in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,000 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Patients Treated With the Woven EndoBridge Device

    Patients with intracranial aneurysms who are treated with the commercially available MicroVention Woven EndoBridge device as part of routine clinical care. This cohort includes both retrospectively identified patients and prospectively enrolled patients. Clinical, procedural, imaging, safety, effectiveness, clinical appropriateness, and health economic outcomes will be collected according to the study protocol.

    Device: Intrasaccular Flow Disruption Device

Interventions

  • DeviceIntrasaccular Flow Disruption Device

    The intervention of interest is treatment of intracranial aneurysms using the commercially available MicroVention Woven EndoBridge device. The device is an intrasaccular flow disruption device used during endovascular treatment according to routine clinical practice and the approved instructions for use. Treatment decisions and procedural details are determined by the treating physician.

    Also known as: Woven EndoBridge, WEB Device, MicroVention WEB Device, Woven EndoBridge Aneurysm Embolization System

06

What researchers measure

Primary outcomes

  1. Incidence of Major Adverse Events

    Major adverse events include unexpected death or major stroke within 30 days after the procedure, and neurological death or major stroke from 31 days to 1 year after the procedure. Major stroke is defined as an ischemic or hemorrhagic stroke associated with an increase of more than 4 points in the NIHSS score.

    Time frame: Up to 1 Year After the Index Procedure

  2. Proportion of Aneurysms With Adequate Occlusion Based on Raymond-Roy Occlusion Classification

    Adequate aneurysm occlusion is defined as Raymond-Roy Occlusion Classification class I or II at the 12-month follow-up. Class I indicates complete occlusion, and class II indicates residual neck without contrast filling of the aneurysm sac.

    Time frame: 12 Months After the Index Procedure

Secondary outcomes

  1. Proportion of Aneurysms With Adequate Occlusion Based on WEB Occlusion Scale

    Adequate aneurysm occlusion will be assessed by an independent imaging core laboratory using the Woven EndoBridge Occlusion Scale. The Woven EndoBridge Occlusion Scale is a categorical angiographic scale ranging from Class A to Class D: Class A indicates complete occlusion, Class B indicates complete occlusion with recess filling, Class C indicates neck remnant, and Class D indicates aneurysm remnant. Adequate occlusion is defined as Class A, Class B, or Class C. Class D indicates inadequate occlusion. This is a categorical scale; higher or lower numerical scores are not applicable.

    Time frame: 12 Months After the Index Procedure

  2. Aneurysm Occlusion Status Based on Raymond-Roy Occlusion Classification and WEB Occlusion Scale

    Aneurysm occlusion status will be assessed by an independent imaging core laboratory using the Raymond-Roy Occlusion Classification and the Woven EndoBridge Occlusion Scale. The Raymond-Roy Occlusion Classification is a categorical angiographic classification ranging from Class I to Class III: Class I indicates complete occlusion, Class II indicates residual neck, and Class III indicates residual aneurysm. The Woven EndoBridge Occlusion Scale is a categorical angiographic scale ranging from Class A to Class D: Class A indicates complete occlusion, Class B indicates complete occlusion with recess filling, Class C indicates neck remnant, and Class D indicates aneurysm remnant. These are categorical scales; higher or lower numerical scores are not applicable.

    Time frame: 12 Months After the Index Procedure

  3. Aneurysm Occlusion Without Rebleeding in Ruptured Aneurysms

    In participants with ruptured aneurysms, aneurysm occlusion status will be assessed together with the absence of rebleeding.

    Time frame: 12 Months After the Index Procedure

  4. Aneurysm Occlusion Without Rebleeding or Retreatment in Aneurysms With Residual Filling

    In aneurysms with residual filling, occlusion status will be assessed together with absence of rebleeding in ruptured aneurysms or absence of retreatment.

    Time frame: 12 Months After the Index Procedure

  5. Stability of Aneurysm Occlusion

    Occlusion stability will be assessed by comparing imaging results between the 6-month and 12-month follow-up visits and classified as unchanged, improved, or worsened.

    Time frame: From 6 Months to 12 Months After the Index Procedure

  6. Aneurysm Recurrence

    Aneurysm recurrence is defined as aneurysm growth or recanalization within 1 year after the index procedure.

    Time frame: Up to 1 Year After the Index Procedure

  7. Aneurysm Retreatment

    The proportion of participants who undergo retreatment of the target aneurysm within 1 year will be assessed.

    Time frame: Up to 1 Year After the Index Procedure

  8. Unplanned Retreatment or Alternative Treatment

    The proportion of participants who undergo unplanned retreatment or alternative treatment due to aneurysm recurrence or residual aneurysm will be assessed.

    Time frame: Up to 1 Year After the Index Procedure

  9. Rebleeding Within 30 Days in Ruptured Aneurysms

    In participants with ruptured aneurysms, rebleeding within 30 days after the procedure will be assessed, excluding intraprocedural rupture or bleeding.

    Time frame: Up to 30 Days After the Index Procedure

  10. Rebleeding Within 1 Year in Ruptured Aneurysms

    In participants with ruptured aneurysms, rebleeding within 1 year after the procedure will be assessed, excluding intraprocedural rupture or bleeding.

    Time frame: Up to 1 Year After the Index Procedure

  11. New Bleeding of the Target Aneurysm in Unruptured Aneurysms

    In participants with unruptured aneurysms, new bleeding of the target aneurysm within 1 year will be assessed, excluding intraprocedural rupture or bleeding.

    Time frame: Up to 1 Year After the Index Procedure

  12. Parent Artery Patency

    Parent artery patency will be assessed at 1 year, defined as less than 50% stenosis of the parent artery or absence of clinical symptoms.

    Time frame: 12 Months After the Index Procedure

  13. Clinical Outcome Measured by Modified Rankin Scale

    Clinical outcome will be assessed using the Modified Rankin Scale (mRS). The Modified Rankin Scale is an ordinal scale ranging from 0 to 6, where 0 indicates no symptoms, 5 indicates severe disability, and 6 indicates death. Higher scores indicate worse functional outcome.

    Time frame: 30 Days, 6 Months, and 12 Months After the Index Procedure

  14. Device-Related Serious Adverse Events

    Serious adverse events related to the study device will be collected and summarized.

    Time frame: Up to 1 Year After the Index Procedure

  15. Procedure-Related Serious Adverse Events

    Serious adverse events related to the procedure will be collected and summarized.

    Time frame: Up to 1 Year After the Index Procedure

  16. Device- or Procedure-Related Adverse Events

    Periprocedural and postprocedural adverse events related to the device or procedure will be collected and summarized.

    Time frame: Up to 1 Year After the Index Procedure

  17. Neurological Events

    Neurological events will include ischemic stroke, hemorrhagic stroke, neurological death, intracerebral hemorrhage, subarachnoid hemorrhage, arterial thrombosis, parent artery or branch artery perforation or rupture, and transient ischemic attack.

    Time frame: Up to 1 Year After the Index Procedure

  18. Proportion of Target Aneurysms With Successful Woven EndoBridge Device Implantation

    Successful device implantation will be assessed using the procedure record and electronic case report form. Successful Woven EndoBridge device implantation is defined as successful deployment and detachment of the Woven EndoBridge device in the target aneurysm during the index procedure. The outcome will be reported as the proportion of target aneurysms with successful device implantation among target aneurysms in which Woven EndoBridge device implantation was attempted. Reasons for unsuccessful implantation, such as inappropriate device size or model, unsuitable target aneurysm anatomy, unfavorable angle, vascular tortuosity preventing access to the lesion, or other reasons, will be recorded when applicable.

    Time frame: During the Index Procedure

Other outcomes

  1. Healthcare resource utilization

    Healthcare resource utilization will be assessed by collecting data on procedure-related and follow-up medical resource use, including length of hospital stay, intensive care unit admission, additional procedures or retreatment, rehospitalization, emergency visits, outpatient visits, imaging examinations, and other aneurysm treatment-related healthcare services.

    Time frame: From the index procedure through 12 months after treatment

  2. Health-related quality of life

    Health-related quality of life will be assessed using protocol-specified patient-reported quality-of-life instruments. Changes in health-related quality-of-life scores from baseline to follow-up will be evaluated.

    Time frame: Baseline and 12 months after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2028, 24 months later.

Of 68 non-industry observational studies under Intracranial Aneurysm, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 145. This study's planned 24 months is below that.

Counting every sponsor, half of 105 studies reached it within 46 months; a quarter within 36 and three quarters within 145.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 2, 2026
StartEst.
Jun 10, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07620626
Collaborators
Shenzhen Second People's Hospital, ZhuHai Hospital, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, Guangdong Second Provincial General Hospital, Zhujiang Hospital, Nanfang Hospital, Southern Medical University, The First Medical Center of Chinese PLA General Hospital, Beijing Chao Yang Hospital, Beijing Tiantan Hospital, Zhongnan Hospital, Tongji Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Huashan Hospital, Fudan University, RenJi Hospital, Ruijin Hospital, Henan Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Nanyang Central Hospital, First Affiliated Hospital Xi'an Jiaotong University, The First Affiliated Hospital of Air Force Medicial University, The Second Affiliated Hospital of Air Force Military Medical University, Sichuan Provincial People's Hospital, West China Hospital, The First Affiliated Hospital of Anhui Medical University, First Affiliated Hospital of Harbin Medical University, The Second Affiliated Hospital of Harbin Medical University, Xiangya Hospital of Central South University, The Second Xiangya Hospital, Central South University, The First Hospital of Jilin University, Second Hospital of Jilin University, Nanjing Gulou Hospital, First Hospital of China Medical University, Qilu Hospital of Shandong University, First Affiliated Hospital of Chongqing Medical University, People's Hospital of Guangxi Zhuang Autonomous Region, The Affiliated Hospital Of Guizhou Medical University, First Affiliated Hospital of Fujian Medical University, MicroVention, Inc., a Terumo company, Anhui Provincial Hospital, Zhongshan Hospital of Hubei Province, Beijing Haidian Hospital, Peking University Third Hospital, Beijing Anzhen Hospital, Yichang Central People's Hospital, The General Hospital of Eastern Theater Command, The General Hospital of Northern Theater Command, Southwest Hospital, China, Guangxi Hospital of the First Affiliated Hospital, Sun Yat-sen University, Affiliated Hospital of Yunnan University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Tangshan Worker's Hospital, The Affiliated Hospital of Qingdao University
Responsible party
Hongqi Zhang, MD (Xuanwu Hospital, Capital Medical University, Xuanwu Hospital, Beijing) — Principal investigator
First posted
Jun 2, 2026
Start date
Jun 10, 2026 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jun 11, 2026

Study contacts

Hongqi Zhang, M.D
Contact
xwzhanghq@163.com
+8613601374152
Xin Su, M.D
Contact
1258940078@qq.com
+8618210685023
Hongqi Zhang
study chair · Xuanwu Hospital, Beijing
Hongqi Zhang
study director · Xuanwu Hospital, Beijing
Xin Su
principal investigator · Xuanwu Hospital, Beijing
Simin Wang
principal investigator · Xuanwu Hospital, Beijing

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion